KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Change in Cash (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Change in Cash for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 1643.1% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $906.0 million through Dec 2025, up 25.83% year-over-year, with the annual reading at $906.0 million for FY2025, 25.83% up from the prior year.
  • Change in Cash hit $1.0 billion in Q4 2025 for Abbott Laboratories, up from $560.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $1.3 billion in Q2 2022 to a low of -$2.1 billion in Q1 2022.
  • Historically, Change in Cash has averaged $84.2 million across 5 years, with a median of $458.0 million in 2021.
  • Biggest five-year swings in Change in Cash: tumbled 274.67% in 2022 and later surged 1643.1% in 2025.
  • Year by year, Change in Cash stood at $497.0 million in 2021, then plummeted by 42.05% to $288.0 million in 2022, then tumbled by 35.07% to $187.0 million in 2023, then crashed by 68.98% to $58.0 million in 2024, then soared by 1643.1% to $1.0 billion in 2025.
  • Business Quant data shows Change in Cash for ABT at $1.0 billion in Q4 2025, $560.0 million in Q3 2025, and $419.0 million in Q2 2025.